Secondary loss of response (LOR) to infliximab (IFX) commonly occurs. One cause is the development of anti-drug antibodies (ADAs). Evidence regarding the optimal management of ADAs is lacking. We aim to identify the best practice of management of ADAs to IFX to avoid discontinuation of therapy and to determine specific ADA cut-off values to determine pre-specified clinical outcomes.
This is a 3-year study of patients receiving IFX who developed ADAs > 8μg/ml. We reviewed the management strategies and subsequent outcomes in patients who developed ADAs.
A total of 132 patients are included. Baseline characteristics include 54% male patients and mean age of 39.4 years. Fifty-two percent (n = 69) of patients discontinued IFX following the development of ADAs, 33.3% (n = 44) sited as secondary to LOR. Both an increase in IFX and adjustments to combination therapy were associated with lower rates of discontinuation of IFX vs no intervention (p value < 0.001, p value < 0.001). An increase in IFX resulted in a significant difference in ADAs/IFX trough levels pre- and post-intervention (p value < 0.001, p value = 0.032). ROC curve analysis yielded significant cut-off values for ADAs and treatment failure (ADA >16μg/ml, AUC 0.642, p value 0.003), steroid use (ADA >19 μg/ml, AUC 0.61, p value 0.048) development of infusion reactions (ADA> 37 μg/ml, AUC 0.68, p value 0.045) and switch to another biologic (ADA >45 μg/ml, AUC 0.739, p value <0.001).
Both escalation of IFX and combination therapy resulted in lower rates of LOR. ROC curve analysis identified significant cut-off values for ADA trough levels and important clinical outcomes.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 337(15):1029–1035
Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJS, Present D, Sands BE, Colombel JF (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353(23):2462–2476
Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, McDonald TJ, McGovern D, Goodhand JR, Ahmad T, Patel V, Mazhar Z, Saich R, Colleypriest B, Tham TC, Iqbal TH, Kaushik V, Murugesan S, Singh S, Weaver S, Preston C, Butt A, Smith M, Basude D, Beale A, Langlands S, Direkze N, Parkes M, Torrente F, de la Revella Negro J, MacDonald CE, Evans SM, Gunasekera AVJ, Thakur A, Elphick D, Shenoy A, Nwokolo CU, Dhar A, Cole AT, Agrawal A, Bridger S, Doherty J, Cooper SC, de Silva S, Mowat C, Mayhead P, Lees C, Jones G, Ahmad T, Hart JW, Gaya DR, Russell RK, Gervais L, Dunckley P, Mahmood T, Banim PJR, Sonwalkar S, Ghosh D, Phillips RH, Azaz A, Sebastian S, Shenderey R, Armstrong L, Bell C, Hariraj R, Matthews H, Jafferbhoy H, Selinger CP, Zamvar V, de Caestecker JS, Willmott A, Miller R, Babu PS, Tzivinikos C, Bloom SL, Chung-Faye G, Croft NM, Fell JME, Harbord M, Hart A, Hope B, Irving PM, Lindsay JO, Mawdsley JE, McNair A, Monahan KJ, Murray CD, Orchard T, Paul T, Pollok R, Shah N, Bouri S, Johnson MW, Modi A, Kabiru KD, Baburajan BK, Bhaduri B, Fagbemi AA, Levison S, Limdi JK, Watts G, Foley S, Ramadas A, MacFaul G, Mansfield J, Grellier L, Morris MA, Tremelling M, Hawkey C, Kirkham S, Charlton CPJ, Rodrigues A, Simmons A, Lewis SJ, Snook J, Tighe M, Goggin PM, de Silva AN, Lal S, Smith MS, Panter S, Cummings JRF, Dharmisari S, Carter M, Watts D, Mahmood Z, McLain B, Sen S, Pigott AJ, Hobday D, Wesley E, Johnston R, Edwards C, Beckly J, Vani D, Ramakrishnan S, Chaudhary R, Trudgill NJ, Cooney R, Bell A, Prasad N, Gordon JN, Brookes MJ, Li A, Gore S (2019) Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol 4(5):341–353
Sazonovs A, Kennedy NA, Moutsianas L, Heap GA, Rice DL, Reppell M, Bewshea CM, Chanchlani N, Walker GJ, Perry MH, McDonald TJ, Lees CW, Cummings JRF, Parkes M, Mansfield JC, Irving PM, Barrett JC, McGovern D, Goodhand JR, Anderson CA, Ahmad T, Patel V, Mazhar Z, Saich R, Colleypriest B, Tham TC, Iqbal TH, Kaushik V, Murugesan S, Singh S, Weaver S, Preston C, Butt A, Smith M, Basude D, Beale A, Langlands S, Direkze N, Parkes M, Torrente F, de la Revella Negro J, Ewen MacDonald C, Evans SM, Gunasekera AVJ, Thakur A, Elphick D, Shenoy A, Nwokolo CU, Dhar A, Cole AT, Agrawal A, Bridger S, Doherty J, Cooper SC, de Silva S, Mowat C, Mayhead P, Lees C, Jones G, Ahmad T, Hart JW, Gaya DR, Russell RK, Gervais L, Dunckley P, Mahmood T, Banim PJR, Sonwalkar S, Ghosh D, Phillips RH, Azaz A, Sebastian S, Shenderey R, Armstrong L, Bell C, Hariraj R, Matthews H, Jafferbhoy H, Selinger CP, Zamvar V, de Caestecker JS, Willmott A, Miller R, Sathish Babu P, Tzivinikos C, Bloom SL, Chung-Faye G, Croft NM, Fell JME, Harbord M, Hart A, Hope B, Irving PM, Lindsay JO, Mawdsley JE, McNair A, Monahan KJ, Murray CD, Orchard T, Paul T, Pollok R, Shah N, Bouri S, Johnson MW, Modi A, Dawa Kabiru K, Baburajan BK, Bhaduri B, Adebayo Fagbemi A, Levison S, Limdi JK, Watts G, Foley S, Ramadas A, MacFaul G, Mansfield J, Grellier L, Morris MA, Tremelling M, Hawkey C, Kirkham S, Charlton CPJ, Rodrigues A, Simmons A, Lewis SJ, Snook J, Tighe M, Goggin PM, de Silva AN, Lal S, Smith MS, Panter S, Cummings F, Dharmisari S, Carter M, Watts D, Mahmood Z, McLain B, Sen S, Pigott AJ, Hobday D, Wesley E, Johnston R, Edwards C, Beckly J, Vani D, Ramakrishnan S, Chaudhary R, Trudgill NJ, Cooney R, Bell A, Prasad N, Gordon JN, Brookes MJ, Li A, Gore S (2020) HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease. Gastroenterology 158(1):189–199
Rosenberg AS (2003) Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev Biol (Basel) 112:15–21
Wong U, Cross RK (2017) Primary and secondary nonresponse to infliximab: mechanisms and countermeasures. Expert Opin Drug Metab Toxicol 13(10):1039–1046
Rojas JR, Taylor RP, Cunningham MR, Rutkoski TJ, Vennarini J, Jang H, Graham MA, Geboes K, Rousselle SD, Wagner CL (2005) Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther 313(2):578–585
Ordas I et al (2012) Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 91(4):635–646
Ding NS, Hart A, De Cruz P (2016) Systematic review: predicting and optimising response to anti-TNF therapy in Crohn’s disease - algorithm for practical management. Aliment Pharmacol Ther 43(1):30–51
Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM (2011) Pharmacokinetic properties of infliximab in children and adults with Crohn’s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther 33(7):946–964
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359(9317):1541–1549
Owczarczyk-Saczonek A, Owczarek W, Osmola-Mańkowska A, Adamski Z, Placek W, Rakowska A (2019) Secondary failure of TNF-alpha inhibitors in clinical practice. Dermatol Ther 32(1):e12760
Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S, Gerson L, Hirano I, Nguyen GC, Rubenstein JH, Smalley WE, Stollman N, Sultan S, Vege SS, Wani SB, Weinberg D, Yang YX (2017) American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology 153(3):827–834
Vande Casteele, N., et al., American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology, 2017. 153(3): p. 835–857.e6
Baert F, Noman M, Vermeire S, van Assche G, D' Haens G, Carbonez A, Rutgeerts P (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 348(7):601–608
Papamichael K et al (2019) Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 17(9):1655–1668.e3
Negoescu DM et al (2019) Proactive vs reactive therapeutic drug monitoring of infliximab in Crohn’s disease: a cost-effectiveness analysis in a simulated cohort. Inflamm Bowel Dis
Papamichael K, Vajravelu RK, Vaughn BP, Osterman MT, Cheifetz AS (2018) Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease. J Crohns Colitis 12(7):804–810
Mc Gettigan N, Keogh A, McCarthy O, McNally M, Deane C, Slattery E (2019) The effects of proactive therapeutic drug monitoring vs reactive therapeutic drug monitoring in a virtual biologic clinic, a retrospective cohort study. GastroHep 1(6):274–283
Papamichael K et al (2017) Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab. Clin Gastroenterol Hepatol 15(10):1580–1588.e3
Vande Casteele N et al (2015) Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 148(7):1320–9.e3
Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS (2014) Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis 20(11):1996–2003
Bodini G, Giannini EG, Savarino V, del Nero L, Lo Pumo S, Brunacci M, de Bortoli N, Jain A, Tolone S, Savarino E (2018) Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease. Dig Liver Dis 50(5):452–456
Ternant D, Aubourg A, Magdelaine-Beuzelin C, Degenne D, Watier H, Picon L, Paintaud G (2008) Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 30(4):523–529
Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, Cézard JP (2006) Clinical and biological consequences of immunization to infliximab in pediatric Crohn’s disease. Clin Immunol 118(1):11–19
Ainsworth MA, Bendtzen K, Brynskov J (2008) Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn’s disease. Am J Gastroenterol 103(4):944–948
Papamichael K, Vajravelu RK, Osterman MT, Cheifetz AS (2018) Long-term outcome of infliximab optimization for overcoming immunogenicity in patients with inflammatory bowel disease. Dig Dis Sci 63(3):761–767
Steenholdt C, Bendtzen K, Brynskov J, Thomsen OØ, Ainsworth MA (2011) Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn’s disease. Scand J Gastroenterol 46(3):310–318
Yanai H et al (2015) Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol 13(3):522–530.e2
Papamichael K, Karatzas P, Mantzaris GJ (2015) Addition of an immunomodulator as a rescue therapy for loss of response to adalimumab dose escalation in patients with Crohn’s disease. J Crohns Colitis 9(7):589–590
Katz L, Gisbert JP, Manoogian B, Lin K, Steenholdt C, Mantzaris GJ, Atreja A, Ron Y, Swaminath A, Shah S, Hart A, Lakatos PL, Ellul P, Israeli E, Svendsen MN, van der Woude JC, Katsanos KH, Yun L, Tsianos EV, Nathan T, Abreu M, Dotan I, Lashner B, Brynskov J, Terdiman JP, Higgins PDR, Chaparro M, Ben-Horin S (2012) Doubling the infliximab dose versus halving the infusion intervals in Crohn’s disease patients with loss of response. Inflamm Bowel Dis 18(11):2026–2033
Velayos FS, Kahn JG, Sandborn WJ, Feagan BG (2013) A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn’s disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol 11(6):654–666
Elias ED, Targownik LE, Singh H, Bernstein CN (2020) A population-based study of combination vs monotherapy of anti-TNF in persons with IBD. Inflamm Bowel Dis 26(1):150–157
The authors would like to thank the Inflammatory Bowel Disease Unit in Beaumont Hospital for supporting the undertaking of this study.
Data and materials availability
Available upon request
Ethics approval and consent to participate
Approval was obtained from the Beaumont Hospital Quality improvement committee to perform the study. Consent was not required as part of the study given the retrospective nature and complete anonymity of the date recorded.
Consent for publication
All authors consent to article publication.
Conflict of interest
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Mc Gettigan, N., Afridi, A.S., Harkin, G. et al. The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease. Int J Colorectal Dis (2021). https://doi.org/10.1007/s00384-021-03855-4
- Ulcerative colitis
- Crohn’s disease